KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Accumulated Depreciation & Amortization (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Accumulated Depreciation & Amortization data on record, last reported at $91.0 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 15.53% year-over-year to $91.0 million; the TTM value through Dec 2025 reached $91.0 million, up 15.53%, while the annual FY2025 figure was $91.0 million, 15.53% up from the prior year.
  • Accumulated Depreciation & Amortization reached $91.0 million in Q4 2025 per PCRX's latest filing, up from $69.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $91.5 million in Q4 2022 and bottomed at $4.9 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $44.3 million, with a median of $39.8 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 319.54% in 2022, then dropped 17.41% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $28.5 million in 2021, then surged by 220.52% to $91.5 million in 2022, then decreased by 17.41% to $75.6 million in 2023, then rose by 4.25% to $78.8 million in 2024, then increased by 15.53% to $91.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $91.0 million in Q4 2025, $69.7 million in Q3 2025, and $48.5 million in Q2 2025.